Stada Enjoys Robust First Half For Generics And Biosimilars

Recently Launched Higher-Strength 100mg/ml Adalimumab Biosimilar

With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.

Europe from space
Stada remains a major player in the EU • Source: Shutterstock

STADA Arzneimittel AG has continued its streak as one of the four largest generics suppliers in Europe, with its Generics sales climbing by 8% as reported and by 6% in constant currencies to €697.1m ($697.1m) in the first half of 2022.

[Sidebar#GB151760]

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business